Bausch Health Companies Inc
🇺🇸XNYS.BHCUnited StatesHealthcare
Price$5.66+0.02 (+0.35%)
Latest anomalies
Very negative 9 detected in the last 120 days
- High: 7
- Medium: 10
- Low: 0
Debt to equity: below the 1st percentile of its industry and country peers
Asset turnover: declining while the industry median improves
Debt to equity: declining while the industry median improves
Dividend yield: declining while the industry median improves
Dividend yield: below the 10th percentile of its industry and country peers
Free with a Finzer account.
Profile
- Healthcare
- Drug Manufacturers - Specialty & Generic
- United States
Identity
- Exchange
- New York Stock Exchange . XNYS
- Type
- Stock
- ISIN
- CA0717341071
- CUSIP
- 09067J109
Company
- Employees
- 20,700
- Headquarters
- Laval, United States
- Website
- https://www.bauschhealth.com
Market
- Shares outstanding
- 374M
- Market cap
- $2.09B
Key dates
- Next earnings
- Nov 4, 2026
Highlights
- Market cap
- $2.11B
- EPS LTM
- $0.26
- P/E LTM
- 35.52
- Div yield
- 0%
Fundamentals (LTM)
- Revenue
- $9.86B+7.13%up year on year
- Net income
- $98M+120.81%up year on year
- Gross margin
- 70.7%-0.14%down year on year
- Free cash flow
- $1.1B+21.19%up year on year
Latest news
Business summary
Bausch Health Companies Inc is a company in the healthcare sector, listed on New York Stock Exchange (United States) under the ticker BHC. Its market capitalisation is $2.09B, from 374M shares outstanding, as of . Across the 250 trading sessions to the shares traded between $4.34 and $8.00, and the last close of $5.66 sits 36% of the way up that range. The company is headquartered in Laval, United States, and employs about 20,700 people. This is the New York Stock Exchange listing of Bausch Health Companies Inc; its primary listing is BHC on Toronto Stock Exchange.
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company, develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, generic pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health in the United States and internationally. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; dermatology products; generic pharmaceutical products; and dentistry products. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.